Answers are grounded in this paper and cite their sources.
Real-world survey assesses medication satisfaction in Chinese NMOSD patients treated with inebilizumab, suggesting implications for care.
To assess medication satisfaction, quality-of-life improvements among Chinese patients with neuromyelitis optica spectrum disorder (NMOSD) treated with inebilizumab in real-world settings, and to provide evidence supporting clinical decision-making and patient-centered care.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: